Importantly, the adverse prognostic impact of CD300A was validated in seven independent cohorts of AML patients (GSE6891, n = 293; GSE10358, n = 304; GSE37642 [U133A], n = 422; GSE37642 [U133plus2], n = 140; GSE12417 [U133A], n = 163; GSE12417 [U133plus2], n = 79; GSE71014, n = 104) (Figure 4A,C,E‐I) and CN‐AML patients from GSE6891 and GSE10358 cohorts (Figure 4B,D). Here, CD300A is linked to acute myeloid leukemia.